StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3029% above fair value
$515.02−5.64 (-1.08%)

Close on Nov 20, 2026Market cap $130.54BP/E 30.0Yield –

Vertex Pharmaceuticals CEO Pay Ratio by Year

CEO Pay Ratio — Median employee annual total compensation ($) ($)

Vertex Pharmaceuticals CEO Pay Ratio: $264,487 in FY2025, up 7.6% from a year earlier.

Latest, FY2025
264,487
Period ended Dec 31, 2025
Change on a year earlier
+7.6%
245,708 in FY2024
History
7 years
Since FY2019
Sources
7
Documents cited below

Where the FY2025 figure comes from

“In 2025, Dr. Kewalramani’s annual total compensation, as reported in the Summary Compensation Table, was $21,144,261 and the median of the annual total compensation of all employees of the company (other than our Chief Executive Officer) was $264,487. The ratio of annual total compensation for Dr. Kewalramani to that of our median employee’s annual total compensation was approximately 80:1.”

Source: Proxy Statement (DEF 14A) (vrtx-20260402.htm, filed 2026-04-02) ↗

Reported in DEF 14A Proxy Statements (CEO Pay Ratio Disclosure).

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Vertex Pharmaceuticals CEO Pay Ratio ($), annual FY2019–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/median-emp-comp

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?